Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK).

被引：1
|
作者：
Schulte, Johannes H.
Moreno, Lucas
Ziegler, David Simon
Marshall, Lynley V.
Zwaan, C. Michel
Irwin, Meredith
Casanova, Michela
Sabado, Constantino
Wulff, Beate
Stegert, Mario
Wang, Luojun
Hurtado, Felipe K.
Branle, Fabrice
Fischer, Matthias
Geoerger, Birgit
机构：
[1] Charite Berlin Campus Virchow Klinikum, Berlin, Germany
[2] Hosp Univ Nino Jesus, Madrid, Spain
[3] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia
[4] Royal Marsden Hosp, London, England
[5] Inst Canc Res, London, England
[6] Sophia Childrens Univ Hosp, Erasmus MC, Rotterdam, Netherlands
[7] Princess Maxima Ctr Pediat Oncol Utrecht, Rotterdam, Netherlands
[8] Hosp Sick Children, Toronto, ON, Canada
[9] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[10] Hosp Valle De Hebron, Barcelona, Spain
[11] Univ Childrens Hosp III Essen, Essen, Germany
[12] Novartis Pharma AG, Basel, Switzerland
[13] Novartis Pharmaceut, E Hanover, NJ USA
[14] Novartis Inst Biomed Res, Oncol Clin Pharmacol, E Hanover, NJ USA
[15] Novartis Pharmaceut AG, Basel, Switzerland
[16] Univ Childrens Hosp Cologne, Cologne, Germany
[17] Univ Paris Saclay, Gustave Roussy Canc Ctr, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10505
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study
    Tobinai, Kensei
    Uchida, Toshiki
    Fukuhara, Noriko
    Nishikawa, Tomoaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (03) : 366 - 368
  • [32] Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study
    Kensei Tobinai
    Toshiki Uchida
    Noriko Fukuhara
    Tomoaki Nishikawa
    International Journal of Hematology, 2019, 109 : 366 - 368
  • [33] Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
    Zhou, Xiaoyun
    Shou, Jiawei
    Sheng, Jin
    Xu, Chunwei
    Ren, Shengxiang
    Cai, Xiuyu
    Chu, Qian
    Wang, Wenxian
    Zhen, Qinhong
    Zhou, Yuefen
    Li, Wenfeng
    Pan, Hong
    Li, Hongsen
    Sun, Tao
    Cheng, Huanqing
    Wang, Huina
    Lou, Feng
    Rao, Chuangzhou
    Cao, Shanbo
    Pan, Hongming
    Fang, Yong
    CANCER SCIENCE, 2019, 110 (10) : 3382 - 3390
  • [34] Clinical Outcomes of Patients with Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase-Negative (ALCL, ALK-): Analysis of 203 Patients Prospectively Registered in the International T-Cell Project
    Shustov, Andrei
    Cabrera, Maria Elena
    Bellei, Monica
    Ko, Young Hyeh
    Manni, Martina
    Horwitz, Steven M.
    De Souza, Carmino Antonio
    Radford, John A.
    Varela, Sabela Bobillo
    Prates, Maria Virginia
    Ferreri, Andres J. M.
    Chiattone, Carlos
    Spina, Michele
    Vose, Julie M.
    Chiappella, Annalisa
    Laszlo, Daniele
    Marino, Dario
    Stelitano, Caterina
    Federico, Massimo
    BLOOD, 2017, 130
  • [35] Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK plus ) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study
    Scagliotti, G.
    Kim, T. M.
    Crino, L.
    Liu, G.
    Gridelli, C.
    Novello, S.
    Kiura, K.
    Bearz, A.
    Gautschi, O.
    Felip, E.
    Nishio, M.
    Spigel, D. R.
    Mok, T. S. K.
    Urban, P.
    Deudon, S.
    Zheng, C.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] Patient-reported outcomes (PROs) in ASCEND-5: A randomized, phase 3 study of ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase rearranged (ALK plus ) NSCLC previously treated with CT and crizotinib (CRZ)
    Mok, T. S. K.
    Scagliotti, G.
    Kim, T. M.
    Crino, L.
    Liu, G.
    Gridelli, C.
    Novello, S.
    Kiura, K.
    Bearz, A.
    Gautschi, O.
    Felip, E.
    Nishio, M.
    Spigel, D. R.
    Urban, P.
    Deudon, S.
    Zheng, C.
    Shaw, A. T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [37] Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial"
    Sullivan, Ivana
    Planchard, David
    JOURNAL OF THORACIC DISEASE, 2016, 8 (10) : E1287 - E1292
  • [38] Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study
    Chen, Joseph
    O'Gorman, Melissa T.
    James, Lee P.
    Klamerus, Karen J.
    Mugundu, Ganesh
    Pithavala, Yazdi K.
    CLINICAL PHARMACOKINETICS, 2021, 60 (10) : 1313 - 1324
  • [39] Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study
    Joseph Chen
    Melissa T. O’Gorman
    Lee P. James
    Karen J. Klamerus
    Ganesh Mugundu
    Yazdi K. Pithavala
    Clinical Pharmacokinetics, 2021, 60 : 1313 - 1324
  • [40] Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong
    Loong, Herbert H.
    Wong, Carlos K. H.
    Leung, Linda K. S.
    Chan, Catherine P. K.
    Chang, Andrea
    Zhou, Zheng-Yi
    Xie, Jipan
    Gibbs, Meaghan
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2020, 18 (01)
12345